Enzo Biochem

356 articles about Enzo Biochem

• Enzo Biochem Doubles Capacity In Response To Increasing Demand For Covid-19 Testing

  9/8/2020

  Facility in Farmingdale, NY, expanding manufacturing and molecular platform to support rapidly growing demand for testing services from universities, nursing homes, physician offices and urgent care facilities.

• ENZO BIOCHEM TO PROVIDE ACCESS TO COVID-19 TESTING AT MORE THAN 50 NY PHARMACIES IN COLLABORATION WITH CPESN NY

  7/21/2020

  Enzo Biochem, Inc. announced they are partnering to provide COVID-19 testing at 52 of the network’s 155 pharmacies across New York State. This initial pilot was made possible in strong collaboration with Pharmacists’ Society of the State of New York.

• Enzo Biochem Receives Emergency Use Authorization for Proprietary Test System for Detection of Coronavirus SARS-CoV-2Authorization Enables Clinical Labs to Purchase and Use Enzo’s AMPIPROBE® SARS-Cov-2 Test System without Further Validation

  7/13/2020

  Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today announced that it has formally received Emergency Use Authorization (EUA) for its proprietary product for the detection of Coronavirus SARS-CoV-2. The Authorization enables other laboratories to use Enzo’s products with three diverse platforms without requiring further val

• Enzo Biochem to Provide COVID-19 Testing to Farmingdale State College Staff and Students as They Return to Campus

  6/30/2020

  Enzo Biochem, Inc., a leading biosciences and diagnostic company, and Farmingdale State College announced they are partnering to provide molecular and antibody testing for COVID-19 to the campus community as the college reopens this summer and begins classes in the fall.

• Enzo Announces Issuance of U.S. Patent for Methods of Treating Liver Cancer Using Proprietary Compound SK1-I

  6/23/2020

  Enzo Biochem, Inc. (NYSE: ENZ), a leading biosciences and diagnostics company, today announced it has received a patent for the treatment of liver cancer, U.S. Patent No. 10,675,255 entitled Sphingosine Pathway Modulating Compounds for the Treatment of Cancers . Enzo’s patent is directed to methods for treating hepatocellular carcinoma (HCC), the

• Enzo Biochem Reports Third Quarter 2020 Financial Results

  6/8/2020

  Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today reported results for the third quarter ended April 30, 2020.

• Enzo Biochem to Announce Third Quarter 2020 Financial Results on Monday June 8, 2020

  6/3/2020

  Enzo Biochem, Inc.  (NYSE: ENZ) a leading biosciences and diagnostics company, today announced that it will release its third quarter 2020 financial results after the market closes on Monday June 8, 2020.

• Enzo Biochem Launches Proprietary Test for Detection of Coronavirus SARS-CoV-2 IgG Antibody Under FDA’s Emergency Use Authorization

  5/20/2020

  Second Product Offering to Expand Disease Management within Enzo’s Comprehensive COVID-19 Program Enzo’s ELISA Kit for SARS-CoV-2 IgG Antibody Demonstrates High Specificity and High Sensitivity Detection    NEW YORK, NY, May 20, 2020 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today announced that it is currently offering a SARS-CoV-2 IgG ELISA assay kit for serological detection of IgG antibodies against the novel coronavirus under th

• 

  Biopharma Update on the Novel Coronavirus: May 20

  5/20/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 20, 2020.

• Enzo Announces Issuance of U.S. Patent for Methods of Producing Monoclonal Antibodies Against Osteoporosis Drug Target Sclerostin

  5/12/2020

  Enzo Biochem, Inc. a leading biosciences and diagnostics company, announced the recent issuance of U.S. Patent No. 10,626,170 entitled Sulfonated Sclerostin, Antibodies, Epitopes and Methods for Identification and Use Therefor.

• Enzo Announces Issuance of U.S. Patent for Methods of Using Proprietary Compound SK1-I in Patients; Exploring Options for Development as a Potential Treatment for COVID-19

  4/29/2020

  Enzo Biochem, Inc.  (NYSE: ENZ), a leading biosciences and diagnostics company, today announced the recent issuance of U.S. Patent No. 10,624,863 entitled Sphingosine Kinase Type 1 Inhibitors and Uses Thereof.  The patent is directed to methods for inhibiting the enzyme Sphingosine kinase 1 in patients using the company’s proprietary compound SK1-I and related Sphingosine kinase 1 inhibitors.  In February, Enzo reported the publication of work

• Enzo Biochem Launches Proprietary COVID-19 Diagnostic Test Under FDA’s Emergency Use Authorization

  4/23/2020

  First Test Offering Within Enzo’s Comprehensive COVID-19 Program Proprietary Molecular Diagnostic Kits Offer Improved Scale, Throughput, and Sensitivity NEW YORK--( BUSINESS WIRE )-- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostic company, today announced its Comprehensive COVID-19 Program incorporating its molecular diagnostic virus screening products, detection for immunity through IgG/IgM serological ELISA products, det

• Enzo Biochem’s Clinical Labs Subsidiary Launches Drive-Through Facility to Provide COVID-19 Testing on Long Island

  3/24/2020

  Enzo Biochem, Inc., a leading biotechnology and diagnostic company, announced its wholly owned subsidiary, Enzo Clinical Labs, Inc., has expanded its screening services for COVID-19.

• Enzo Biochem’s Full Service Clinical Laboratory to Launch Coronavirus (COVID-19) Testing Services Next Week

  3/6/2020

  Enzo Biochem, Inc. (NYSE:ENZ) today announced that its wholly owned subsidiary, Enzo Clinical Labs, Inc., will begin accepting specimens for novel Coronavirus (COVID-19) testing next week.

• Enzo Biochem Reports Fiscal Second Quarter Results 2020

  3/5/2020

  Approval of Proprietary GenFlex™ Platform Is Significant Milestone and Validates Ability to Leverage Leading Intellectual Property

• Enzo Biochem Schedules Teleconference to Discuss Second Quarter 2020 Results Friday, March 6, 2020 at 8:30 AM E.T.

  3/3/2020

  Enzo Biochem, Inc . (NYSE:ENZ) will hold a conference call to discuss fiscal 2020 second quarter results on Friday, March 6, 2020, at 8:30 AM E.T.

• Enzo Biochem Announces Preliminary Results of Voting at Annual Shareholder Meeting

  2/25/2020

  Feb. 25, 2020 14:59 UTC NEW YORK--( BUSINESS WIRE )-- Enzo Biochem (NYSE:ENZ) announced preliminary results of voting at the 2019 Annual Shareholder meeting held today. According to these preliminary results, shareholders did not approve the proposal to increase the size of Board, voted to elect Fabian Blank, Peter Clemens and Rebecca Fischer to the Board of Directors, approved the non-binding advisory resolution on executive compensation, ratified the appointment of Enzo’s ind

• Enzo Biochem Reports Publication of Study Detailing Promising Activity of Drug Candidate SK1‑I in a Model of Lupus

  2/19/2020

  Feb. 19, 2020 13:30 UTC Drug Candidate SK1‑I Shown to Markedly Decrease Lupus-Associated Immune Criteria and Kidney Inflammation in Preclinical Study Study is Further Confirmation of Enzo Biochem’s Proprietary Compound’s Potential for Treatment of this and other Autoimmune Diseases NEW YORK--( BUSINESS WIRE )-- Enzo Biochem, Inc. (NYSE:ENZ) today announced the publication of a study in The FASEB Journal by academic researchers that shows drug candidate “SK1‑I,” the c

• ISS Recommends Shareholders Vote AGAINST Enzo Proposal to Increase Size of Board

  2/19/2020

  Leading Proxy Advisory Firm Calls Claim by Enzo’s Board that its Actions are Somehow “Shareholder Friendly” to be “Not Only Misleading, but Arguably Deceptive.”

• Enzo Biochem Announces Significant Milestone with Approval of Proprietary GenFlex Platform

  2/11/2020

  Feb. 11, 2020 13:30 UTC New York State Department of Health Approves Tests on GenFlex Platform, Enzo Biochem’s First Commercially Available High-Throughput Open Platform Approval of Gynecological Tests (CT/NG/TV) on GenFlex Platform Represents Sea-Change in Providing Cost-Effective Comprehensive Menu of Molecular Diagnostic Tests Genflex addresses the $450 million annualized global CT/NG/TV diagnostic market as well as the $1.3 billion Women’s Health market Further Valid